Oral Solid Dosage Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report, By Product (Tablets, Capsules, Granules Powder, Others); By Mechanism; By End-User; By Region; Segment Forecast, 2024- 2032

Oral Solid Dosage Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report, By Product (Tablets, Capsules, Granules Powder, Others); By Mechanism; By End-User; By Region; Segment Forecast, 2024- 2032

The global oral solid dosage contract manufacturing market size is expected to reach USD 57.02 billion by 2032, according to a new study by Polaris Market Research. The report “Oral Solid Dosage Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report, By Product (Tablets, Capsules, Granules Powder, Others); By Mechanism; By End-User; By Region; Segment Forecast, 2024- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Contract manufacturers differentiate themselves by offering unique Oral Solid Dosage (OSD) forms, thanks to ongoing improvements in formulation technology. Furthermore, the OSD contract manufacturing sector is seeing a growth in the use of automation and robotics. This technology integration reduces human error, improves manufacturing precision, and increases overall operational efficiency.

Strong technical competence in pharmaceutical formulation coupled with a dedication to regulatory adherence allows businesses to provide superior services while adjusting to changing industry norms. Bigger Contract Manufacturing Organizations (CMOs) take advantage of economies of scale, which let them invest in cutting-edge technology, negotiate advantageous contracts with suppliers, and provide competitive pricing. Their entire profitability and competitiveness in the market are improved by this strategic approach.

A significant increase in the use of generic drugs might be attributed to the growing need for affordable healthcare solutions. Generic medications are preferred because of their simple production, durability, and excellent patient compliance, particularly in oral solid dosage forms like tablets and capsules. Progress in the sector is largely due to the wide range of generic medications available in oral solid dose forms.

However, ensuring the continuous and high-quality production of oral solid dosage forms presents a formidable challenge. The maintenance of rigorous quality control standards throughout the manufacturing process is essential but can be intricate. Any shortcomings in quality control have the potential to lead to product recalls, tarnished reputations, and legal consequences, acting as a constraint on the market.

Moreover, the oral solid dosage contract manufacturing market is susceptible to disruptions in the global supply chain, as demonstrated by events like the COVID-19 pandemic. Supply chain disruptions lead to delays in production, shortages, and increased costs, impacting the overall market dynamics.

Oral Solid Dosage Contract Manufacturing Market Report Highlights

In 2023, the capsules segment is expected to witness highest growth during forecast period owing to rapid disintegration, and absorption

Controlled release segment is expected to dominate the oral solid dosage contract manufacturing market during forecast period.

Large enterprises segment is expected to dominate the oral solid dosage contract manufacturing market during forecast period. This is due to citing quality and reliability as their foremost considerations

In 2023, Asia-Pacific accounted for the largest revenue share due to social insurance schemes and continually improving economic conditions in the region.

The market is highly competitive owing to the existence of market players with a global presence, including Alkem Laboratories, Catalent, Inc., Dr. Reddy's Laboratories, Evonik Industries AG, Famar Health Care Services, among others.

Polaris Market Research has segmented the oral solid dosage contract manufacturing market report based on product, mechanism, end-user and region:

Oral Solid Dosage Contract Manufacturing, Product Outlook (Revenue - USD Billion, 2019 - 2032)

Tablets

Capsules

Granules

Powder

Others

Oral Solid Dosage Contract Manufacturing, Mechanism Outlook (Revenue - USD Billion, 2019 - 2032)

Controlled Release

Immediate Release

Delayed Release

Oral Solid Dosage Contract Manufacturing, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

SMEs

Large Enterprises

Others

Oral Solid Dosage Contract Manufacturing, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

France

Germany

UK

Italy

Netherlands

Spain

Russia

Asia Pacific

Japan

China

India

Malaysia

Indonesia

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa